Tyra Biosciences Inc
TYRA26.040USD
+0.210+0.81%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.39BMarket Cap
LossP/E TTM
More Details of Tyra Biosciences Inc Company
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Tyra Biosciences Inc Info
Ticker SymbolTYRA
Company nameTyra Biosciences Inc
IPO dateSep 15, 2021
CEOHarris (Todd James)
Number of employees60
Security typeOrdinary Share
Fiscal year-endSep 15
Address2656 State Street
CityCARLSBAD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92008
Phone16197284760
Websitehttps://tyra.bio/
Ticker SymbolTYRA
IPO dateSep 15, 2021
CEOHarris (Todd James)
Company Executives of Tyra Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Discovery Officer
Chief Discovery Officer
170.98K
-60.05%
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Rehan Verjee
Mr. Rehan Verjee
Independent Director
Independent Director
--
--
Dr. S. Michael Rothenberg, M.D., Ph.D.
Dr. S. Michael Rothenberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas (Doug) Warner, M.D.
Dr. Douglas (Doug) Warner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bhavesh Ashar
Mr. Bhavesh Ashar
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Discovery Officer
Chief Discovery Officer
170.98K
-60.05%
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
22.86%
Alta Partners
7.64%
Nextech Invest, Ltd.
7.60%
BVF Partners L.P.
6.84%
Canaan Partners
6.76%
Other
48.30%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
22.86%
Alta Partners
7.64%
Nextech Invest, Ltd.
7.60%
BVF Partners L.P.
6.84%
Canaan Partners
6.76%
Other
48.30%
Shareholder Types
Shareholders
Proportion
Venture Capital
39.08%
Hedge Fund
26.71%
Investment Advisor
21.55%
Investment Advisor/Hedge Fund
15.66%
Individual Investor
2.98%
Research Firm
1.31%
Pension Fund
0.22%
Corporation
0.08%
Bank and Trust
0.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
246
56.81M
106.44%
-5.53M
2025Q2
237
58.64M
110.28%
+1.26M
2025Q1
239
56.06M
105.46%
-647.87K
2024Q4
219
50.96M
100.70%
-3.70M
2024Q3
195
53.66M
101.74%
-3.04M
2024Q2
179
53.85M
102.74%
-1.82M
2024Q1
167
53.85M
102.76%
+5.34M
2023Q4
151
42.86M
99.62%
-3.01M
2023Q3
152
44.80M
104.35%
-3.44M
2023Q2
147
44.53M
104.65%
-3.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
12.20M
22.89%
+1.56M
+14.68%
Jun 30, 2025
Alta Partners
4.08M
7.66%
--
--
Jun 30, 2025
Nextech Invest, Ltd.
4.06M
7.61%
--
--
Jun 30, 2025
BVF Partners L.P.
3.94M
7.4%
--
--
Jun 30, 2025
Canaan Partners
3.61M
6.77%
-536.48K
-12.94%
Jun 30, 2025
Commodore Capital LP
3.10M
5.82%
+350.00K
+12.73%
Jun 30, 2025
TCG Crossover Management, LLC
2.90M
5.44%
--
--
Jun 30, 2025
Janus Henderson Investors
2.86M
5.36%
+163.05K
+6.05%
Jun 30, 2025
Vestal Point Capital, LP
2.65M
4.98%
-224.83K
-7.81%
Jun 30, 2025
Kynam Capital Management LP
2.33M
4.37%
-76.07K
-3.16%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
ALPS Medical Breakthroughs ETF
0.34%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Micro-Cap ETF
0.07%
iShares Biotechnology ETF
0.05%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.04%
ALPS Medical Breakthroughs ETF
Proportion0.34%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tyra Biosciences Inc?
The top five shareholders of Tyra Biosciences Inc are:
RA Capital Management, LP holds 12.20M shares, accounting for 22.89% of the total shares.
Alta Partners holds 4.08M shares, accounting for 7.66% of the total shares.
Nextech Invest, Ltd. holds 4.06M shares, accounting for 7.61% of the total shares.
BVF Partners L.P. holds 3.94M shares, accounting for 7.40% of the total shares.
Canaan Partners holds 3.61M shares, accounting for 6.77% of the total shares.
RA Capital Management, LP holds 12.20M shares, accounting for 22.89% of the total shares.
Alta Partners holds 4.08M shares, accounting for 7.66% of the total shares.
Nextech Invest, Ltd. holds 4.06M shares, accounting for 7.61% of the total shares.
BVF Partners L.P. holds 3.94M shares, accounting for 7.40% of the total shares.
Canaan Partners holds 3.61M shares, accounting for 6.77% of the total shares.
What are the top three shareholder types of Tyra Biosciences Inc?
The top three shareholder types of Tyra Biosciences Inc are:
RA Capital Management, LP
Alta Partners
Nextech Invest, Ltd.
RA Capital Management, LP
Alta Partners
Nextech Invest, Ltd.
How many institutions hold shares of Tyra Biosciences Inc (TYRA)?
As of 2025Q3, 246 institutions hold shares of Tyra Biosciences Inc, with a combined market value of approximately 56.81M, accounting for 106.44% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.84%.
What is the biggest source of revenue for Tyra Biosciences Inc?
In --, the -- business generated the highest revenue for Tyra Biosciences Inc, amounting to -- and accounting for --% of total revenue.
